{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T12:42:09Z","timestamp":1780922529832,"version":"3.54.1"},"reference-count":46,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,11,1]],"date-time":"2018-11-01T00:00:00Z","timestamp":1541030400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,9,21]],"date-time":"2018-09-21T00:00:00Z","timestamp":1537488000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"name":"HPV vaccine manufacturer"},{"DOI":"10.13039\/100015160","name":"Hologic","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100015160","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Cepheid"},{"name":"Qiagen"},{"name":"Becton-Dickinson"},{"name":"Euroimmun"},{"name":"SelfScreen"},{"name":"LifeRiver"},{"name":"Genomica"},{"name":"Genefirst"},{"name":"COHEAHR Network","award":["603019"],"award-info":[{"award-number":["603019"]}]},{"name":"7th Framework Programme of DG Research and Innovation, European Commission"},{"name":"Becton"},{"name":"Dickinson and Company"},{"name":"Genomica SAU"},{"name":"Agena Biotech Gmbh"},{"name":"Zhanghai Biotech"},{"name":"GeneFirst"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Clinical Virology"],"published-print":{"date-parts":[[2018,11]]},"DOI":"10.1016\/j.jcv.2018.09.012","type":"journal-article","created":{"date-parts":[[2018,9,17]],"date-time":"2018-09-17T16:48:15Z","timestamp":1537202895000},"page":"64-71","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":43,"special_numbering":"C","title":["The Valgent4 protocol: Robust analytical and clinical validation of 11 HPV assays with genotyping on cervical samples collected in SurePath medium"],"prefix":"10.1016","volume":"108","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4853-6747","authenticated-orcid":false,"given":"Jesper","family":"Bonde","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ditte M\u00f8ller","family":"Ejegod","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kate","family":"Cuschieri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joakim","family":"Dillner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dani\u00eblle A.M.","family":"Heideman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wim","family":"Quint","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miguel Angel","family":"Pavon Ribas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizaveta","family":"Padalko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irene Kraus","family":"Christiansen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lan","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Arbyn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.jcv.2018.09.012_bib0005","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/S1470-2045(09)70096-8","article-title":"A review of human carcinogens\u2013part B: biological agents","volume":"10","author":"Bouvard","year":"2009","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.jcv.2018.09.012_bib0010","series-title":"Human Papilomavirus","first-page":"90","article-title":"IARCH monographs on the evaluation of carconogenic risks of humans","author":"Group IMw","year":"2007"},{"key":"10.1016\/j.jcv.2018.09.012_bib0015","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.pvr.2017.10.003","article-title":"Surgical staging identified false HPV-negative cases in a large series of invasive cervical cancers","volume":"4","author":"Petry","year":"2017","journal-title":"Papillomavirus Res."},{"issue":"5","key":"10.1016\/j.jcv.2018.09.012_bib0020","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1111\/cyt.12083","article-title":"Understanding HPV tests and their appropriate applications","volume":"24","author":"Cubie","year":"2013","journal-title":"Cytopathology"},{"issue":"Suppl. 5","key":"10.1016\/j.jcv.2018.09.012_bib0025","doi-asserted-by":"crossref","first-page":"F88","DOI":"10.1016\/j.vaccine.2012.06.095","article-title":"Evidence regarding human papillomavirus testing in secondary prevention of cervical cancer","volume":"30","author":"Arbyn","year":"2012","journal-title":"Vaccine"},{"issue":"3","key":"10.1016\/j.jcv.2018.09.012_bib0030","article-title":"Human papillomavirus testing versus repeat cytology for triage of minor cytological cervical lesions","author":"Arbyn","year":"2013","journal-title":"Cochrane Database Syst. Rev."},{"issue":"9916","key":"10.1016\/j.jcv.2018.09.012_bib0035","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1016\/S0140-6736(13)62218-7","article-title":"Efficacy of HPV-based screening for prevention of invasive cervical cancer: follow-up of four European randomised controlled trials","volume":"383","author":"Ronco","year":"2014","journal-title":"Lancet"},{"issue":"Suppl. 5","key":"10.1016\/j.jcv.2018.09.012_bib0040","doi-asserted-by":"crossref","first-page":"F100","DOI":"10.1016\/j.vaccine.2012.04.105","article-title":"Nucleic acid tests for the detection of alpha human papillomaviruses","volume":"30","author":"Poljak","year":"2012","journal-title":"Vaccine"},{"issue":"Suppl. 1","key":"10.1016\/j.jcv.2018.09.012_bib0045","doi-asserted-by":"crossref","first-page":"S14","DOI":"10.1016\/j.jcv.2015.09.014","article-title":"VALGENT: a protocol for clinical validation of human papillomavirus assays","volume":"76","author":"Arbyn","year":"2016","journal-title":"J. Clin. Virol."},{"issue":"14","key":"10.1016\/j.jcv.2018.09.012_bib0050","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1093\/jnci\/dji187","article-title":"The elevated 10-year risk of cervical precancer and cancer in women with human papillomavirus (HPV) type 16 or 18 and the possible utility of type-specific HPV testing in clinical practice","volume":"97","author":"Khan","year":"2005","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.jcv.2018.09.012_bib0055","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.pvr.2016.03.002","article-title":"Human papillomavirus detection in cervical neoplasia attributed to 12 high-risk human papillomavirus genotypes by region","volume":"2","author":"Castellsague","year":"2016","journal-title":"Papillomavirus Res."},{"key":"10.1016\/j.jcv.2018.09.012_bib0060","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.pvr.2016.05.004","article-title":"Need for expanded HPV genotyping for cervical screening","volume":"2","author":"Cuzick","year":"2016","journal-title":"Papillomavirus Res."},{"issue":"10","key":"10.1016\/j.jcv.2018.09.012_bib0065","doi-asserted-by":"crossref","first-page":"1997","DOI":"10.1158\/1055-9965.EPI-14-0410","article-title":"Attribution of 12 high-risk human papillomavirus genotypes to infection and cervical disease","volume":"23","author":"Joura","year":"2014","journal-title":"Cancer Epidemiol. Biomarkers Prev."},{"issue":"5","key":"10.1016\/j.jcv.2018.09.012_bib0070","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1002\/ijc.29085","article-title":"Long-term HPV type-specific risks of high-grade cervical intraepithelial lesions: a 14-year follow-up of a randomized primary HPV screening trial","volume":"136","author":"Smelov","year":"2015","journal-title":"Int. J. Cancer"},{"issue":"2","key":"10.1016\/j.jcv.2018.09.012_bib0075","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1007\/s10552-013-0320-z","article-title":"Carcinogenic HPV prevalence and age-specific type distribution in 40,382 women with normal cervical cytology, ASCUS\/LSIL, HSIL, or cervical cancer: what is the potential for prevention?","volume":"25","author":"Kjaer","year":"2014","journal-title":"Cancer Causes Control"},{"issue":"4","key":"10.1016\/j.jcv.2018.09.012_bib0080","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1002\/path.4424","article-title":"Are 20 human papillomavirus types causing cervical cancer?","volume":"234","author":"Arbyn","year":"2014","journal-title":"J. Pathol."},{"issue":"1-2","key":"10.1016\/j.jcv.2018.09.012_bib0085","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1016\/j.virol.2013.07.015","article-title":"A systematic review of the prevalence of mucosal and cutaneous human papillomavirus types","volume":"445","author":"Bzhalava","year":"2013","journal-title":"Virology"},{"issue":"4","key":"10.1016\/j.jcv.2018.09.012_bib0090","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1002\/ijc.25396","article-title":"Human papillomavirus type distribution in 30,848 invasive cervical cancers worldwide: variation by geographical region, histological type and year of publication","volume":"128","author":"Li","year":"2011","journal-title":"Int. J. Cancer"},{"issue":"19","key":"10.1016\/j.jcv.2018.09.012_bib0095","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.1093\/jnci\/djq356","article-title":"Long-term absolute risk of cervical intraepithelial neoplasia grade 3 or worse following human papillomavirus infection: role of persistence","volume":"102","author":"Kjaer","year":"2010","journal-title":"J. Natl. Cancer Inst."},{"issue":"13","key":"10.1016\/j.jcv.2018.09.012_bib0100","doi-asserted-by":"crossref","first-page":"1732","DOI":"10.1016\/j.ejca.2015.06.001","article-title":"Human papillomavirus genotype attribution for HPVs 6, 11, 16, 18, 31, 33, 45, 52 and 58 in female anogenital lesions","volume":"51","author":"Serrano","year":"2015","journal-title":"Eur. J. Cancer"},{"issue":"12","key":"10.1016\/j.jcv.2018.09.012_bib0105","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1016\/S1473-3099(17)30468-1","article-title":"Changes in the prevalence of human papillomavirus following a national bivalent human papillomavirus vaccination programme in Scotland: a 7-year cross-sectional study","volume":"17","author":"Kavanagh","year":"2017","journal-title":"Lancet Infect. Dis."},{"issue":"2","key":"10.1016\/j.jcv.2018.09.012_bib0110","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1097\/AOG.0000000000000669","article-title":"Use of primary high-risk human papillomavirus testing for cervical cancer screening: interim clinical guidance","volume":"125","author":"Huh","year":"2015","journal-title":"Obstet. Gynecol."},{"issue":"2","key":"10.1016\/j.jcv.2018.09.012_bib0115","doi-asserted-by":"crossref","first-page":"118","DOI":"10.7326\/M15-2735","article-title":"Genotyping for human papillomavirus types 16 and 18 in women with minor cervical lesions: a systematic review and meta-analysis","volume":"166","author":"Arbyn","year":"2017","journal-title":"Ann. Intern. Med."},{"issue":"3","key":"10.1016\/j.jcv.2018.09.012_bib0120","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1002\/ijc.24010","article-title":"Guidelines for human papillomavirus DNA test requirements for primary cervical cancer screening in women 30 years and older","volume":"124","author":"Meijer","year":"2009","journal-title":"Int. J. Cancer Suppl."},{"issue":"9","key":"10.1016\/j.jcv.2018.09.012_bib0125","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1016\/j.cmi.2015.04.015","article-title":"Which high-risk HPV assays fulfil criteria for use in primary cervical cancer screening?","volume":"21","author":"Arbyn","year":"2015","journal-title":"Clin. Microbiol. Infect."},{"key":"10.1016\/j.jcv.2018.09.012_bib0130","first-page":"S3","article-title":"Clinical validation of the BD onclarity HPV assay using a non-inferiority test","author":"Ejegod","year":"2013","journal-title":"Med. Microbiol. Diagn"},{"issue":"9","key":"10.1016\/j.jcv.2018.09.012_bib0135","doi-asserted-by":"crossref","first-page":"2267","DOI":"10.1128\/JCM.00508-16","article-title":"The BD onclarity HPV assay on samples collected in SurePath medium meets the international guidelines for human papillomavirus test requirements for cervical screening","volume":"54","author":"Ejegod","year":"2016","journal-title":"J. Clin. Microbiol."},{"issue":"11","key":"10.1016\/j.jcv.2018.09.012_bib0140","doi-asserted-by":"crossref","first-page":"3983","DOI":"10.1128\/JCM.05552-11","article-title":"Clinical validation of the cobas 4800 HPV test for cervical screening purposes","volume":"49","author":"Heideman","year":"2011","journal-title":"J. Clin. Microbiol."},{"issue":"3","key":"10.1016\/j.jcv.2018.09.012_bib0145","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1128\/JCM.01743-09","article-title":"Comparison of the clinical performance of PapilloCheck human papillomavirus detection with that of the GP5+\/6+-PCR-enzyme immunoassay in population-based cervical screening","volume":"48","author":"Hesselink","year":"2010","journal-title":"J. Clin. Microbiol."},{"issue":"7","key":"10.1016\/j.jcv.2018.09.012_bib0150","doi-asserted-by":"crossref","first-page":"2409","DOI":"10.1128\/JCM.00633-13","article-title":"Clinical validation of the Abbott RealTime High Risk HPV assay according to the guidelines for human papillomavirus DNA test requirements for cervical screening","volume":"51","author":"Hesselink","year":"2013","journal-title":"J. Clin. Microbiol."},{"key":"10.1016\/j.jcv.2018.09.012_bib0155","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.jcv.2016.01.009","article-title":"Clinical validation of Anyplex II HPV HR Detection according to the guidelines for HPV test requirements for cervical cancer screening","volume":"76","author":"Hesselink","year":"2016","journal-title":"J. Clin. Virol."},{"key":"10.1016\/j.jcv.2018.09.012_bib0160","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.jcv.2017.12.001","article-title":"Assessment of the Roche linear array HPV genotyping test within the VALGENT framework","volume":"98","author":"Xu","year":"2018","journal-title":"J. Clin. Virol."},{"key":"10.1016\/j.jcv.2018.09.012_bib0165","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.jcv.2018.01.016","article-title":"Continuing global improvement in human papillomavirus DNA genotyping services: The 2013 and 2014 HPV LabNet international proficiency studies","volume":"101","author":"Eklund","year":"2018","journal-title":"J. Clin. Virol."},{"key":"10.1016\/j.jcv.2018.09.012_bib0170","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.virol.2018.04.003","article-title":"Towards quality and order in human papillomavirus research","volume":"519","author":"Muhr","year":"2018","journal-title":"Virology"},{"issue":"7","key":"10.1016\/j.jcv.2018.09.012_bib0175","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1111\/aogs.13313","article-title":"An overview of cervical cancer epidemiology and prevention in Scandinavia","volume":"97","author":"Pedersen","year":"2018","journal-title":"Acta Obstet. Gynecol. Scand."},{"key":"10.1016\/j.jcv.2018.09.012_bib0180","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.pvr.2016.01.003","article-title":"Clinical and analytical performance of the BD Onclarity HPV assay for detection of CIN2+ lesions on SurePath samples","volume":"2","author":"Ejegod","year":"2016","journal-title":"Papillomavirus Res."},{"issue":"3","key":"10.1016\/j.jcv.2018.09.012_bib0185","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1158\/1055-9965.EPI-12-1067","article-title":"Viral load of high-risk human papillomaviruses as reliable clinical predictor for the presence of cervical lesions","volume":"22","author":"Schmitt","year":"2013","journal-title":"Cancer Epidemiol. Biomarkers Prev."},{"issue":"10","key":"10.1016\/j.jcv.2018.09.012_bib0190","doi-asserted-by":"crossref","first-page":"2395","DOI":"10.1002\/ijc.27891","article-title":"Prevalence and viral load of 51 genital human papillomavirus types and three subtypes","volume":"132","author":"Schmitt","year":"2013","journal-title":"Int. J. Cancer"},{"issue":"5","key":"10.1016\/j.jcv.2018.09.012_bib0195","doi-asserted-by":"crossref","first-page":"1458","DOI":"10.1128\/JCM.00087-13","article-title":"Multiple human papillomavirus infections with high viral loads are associated with cervical lesions but do not differentiate grades of cervical abnormalities","volume":"51","author":"Schmitt","year":"2013","journal-title":"J. Clin. Microbiol."},{"issue":"9","key":"10.1016\/j.jcv.2018.09.012_bib0200","doi-asserted-by":"crossref","first-page":"2337","DOI":"10.1128\/JCM.00897-16","article-title":"Performance of a cartridge-based assay for detection of clinically significant human papillomavirus (HPV) infection: lessons from VALGENT (validation of HPV genotyping tests)","volume":"54","author":"Cuschieri","year":"2016","journal-title":"J. Clin. Microbiol."},{"issue":"10","key":"10.1016\/j.jcv.2018.09.012_bib0205","doi-asserted-by":"crossref","first-page":"3272","DOI":"10.1128\/JCM.01366-15","article-title":"Clinical and analytical performance of the onclarity HPV assay using the VALGENT framework","volume":"53","author":"Cuschieri","year":"2015","journal-title":"J. Clin. Microbiol."},{"issue":"11","key":"10.1016\/j.jcv.2018.09.012_bib0210","doi-asserted-by":"crossref","first-page":"3996","DOI":"10.1128\/JCM.01962-14","article-title":"Clinical evaluation of a GP5+\/6+-based luminex assay having full high-risk human papillomavirus genotyping capability and an internal control","volume":"52","author":"Geraets","year":"2014","journal-title":"J. Clin. Microbiol."},{"key":"10.1016\/j.jcv.2018.09.012_bib0215","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.jcv.2016.05.004","article-title":"Clinical and analytical performance of the PapilloCheck HPV-Screening assay using the VALGENT framework","volume":"81","author":"Heard","year":"2016","journal-title":"J. Clin. Virol."},{"issue":"12","key":"10.1016\/j.jcv.2018.09.012_bib0220","doi-asserted-by":"crossref","first-page":"3544","DOI":"10.1128\/JCM.01282-17","article-title":"Evaluation of the clinical performance of the HPV-Risk assay using the VALGENT-3 panel","volume":"55","author":"Polman","year":"2017","journal-title":"J. Clin. Microbiol."},{"issue":"12","key":"10.1016\/j.jcv.2018.09.012_bib0225","doi-asserted-by":"crossref","first-page":"4391","DOI":"10.1128\/JCM.02716-14","article-title":"Clinical validation of the Cervista HPV HR test according to the international guidelines for human papillomavirus test requirements for cervical cancer screening","volume":"52","author":"Boers","year":"2014","journal-title":"J. Clin. Microbiol."},{"issue":"11","key":"10.1016\/j.jcv.2018.09.012_bib0230","doi-asserted-by":"crossref","first-page":"3653","DOI":"10.1128\/JCM.01517-13","article-title":"The Aptima HPV assay fulfills the cross-sectional clinical and reproducibility criteria of international guidelines for human papillomavirus test requirements for cervical screening","volume":"51","author":"Heideman","year":"2013","journal-title":"J. Clin. Microbiol."}],"container-title":["Journal of Clinical Virology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1386653218302439?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1386653218302439?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,7,10]],"date-time":"2024-07-10T12:14:24Z","timestamp":1720613664000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1386653218302439"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,11]]},"references-count":46,"alternative-id":["S1386653218302439"],"URL":"https:\/\/doi.org\/10.1016\/j.jcv.2018.09.012","relation":{},"ISSN":["1386-6532"],"issn-type":[{"value":"1386-6532","type":"print"}],"subject":[],"published":{"date-parts":[[2018,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The Valgent4 protocol: Robust analytical and clinical validation of 11 HPV assays with genotyping on cervical samples collected in SurePath medium","name":"articletitle","label":"Article Title"},{"value":"Journal of Clinical Virology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jcv.2018.09.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}